Cost-effectiveness of denosumab as a bone protective agent for patients with castration resistant prostate cancer
{{output}}
Fortunately, novel agents are nowadays available for the management of patients with castration-resistant prostate cancer (CRPC). Denosumab is a new bone-protective agent, approved for the prevention and management of skeletal-related events. Studies have demo... ...
